Sandoz Group AG

Swiss Stock Exchange SDZ.SW

Sandoz Group AG EBITDA for the year ending December 31, 2023: USD 857.00 M

Sandoz Group AG EBITDA is USD 857.00 M for the year ending December 31, 2023, a -44.16% change year over year. EBITDA means earnings before interest, taxes, depreciation, and amortization, which measures a company's operating performance by excluding non-operating expenses.
  • Sandoz Group AG EBITDA for the year ending December 31, 2022 was USD 1.53 B, a -8.57% change year over year.
  • Sandoz Group AG EBITDA for the year ending December 31, 2021 was USD 1.68 B, a 30.77% change year over year.
  • Sandoz Group AG EBITDA for the year ending December 31, 2020 was USD 1.28 B.
Key data
Date EBITDA Net Income EPS (Diluted) Shares (Diluted, Weighted)
Market news
Swiss Stock Exchange: SDZ.SW

Sandoz Group AG

CEO Mr. Richard Saynor
IPO Date Oct. 3, 2023
Location Switzerland
Headquarters Suurstoffi 14
Employees 22,633
Sector Health Care
Industries
Pharmaceuticals Biotechnology
Description

Sandoz Group AG develops, manufactures, and markets generic pharmaceuticals and biosimilars worldwide. It develops, manufactures, and markets finished dosage forms of small molecule pharmaceuticals to third parties. It also provides protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services; and anti-infectives, such as active pharmaceutical ingredients and intermediates primarily antibiotics. The company was founded in 1886 and is headquartered in Rotkreuz, Switzerland.

StockViz Staff

January 15, 2025

Any question? Send us an email